Patient-Derived Xenografts as Pre-clinical Models of Response to Chemotherapy
Ovarian high-grade serous cancer (HGSC) is the most lethal gynecologic malignancy and well-characterized models may improve patient outcomes. Patient-derived xenografts (PDXs) recapitulate disease heterogeneity; however, to be useful in predicting response to novel chemotherapeutics, they must refle...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/65546 |